v3.26.1
Earnings (Loss) Per Share
6 Months Ended
Jun. 30, 2026
Earnings Per Share [Abstract]  
Earnings (Loss) Per Share Earnings (Loss) Per Share
Basic earnings (loss) per share is calculated by dividing net income (loss) by the weighted-average common shares outstanding. Diluted net earnings per share is computed by dividing net income (loss) by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Pre-funded warrants to purchase 5,215,000 shares of the Company's common stock for the three and six months ended June 30, 2026, and 7,500,000 shares of the Company's common stock for the three and six months ended June 30, 2025, were included in the weighted-average common shares outstanding used in calculating basic and diluted net income (loss) per share, as the exercise price of the pre-funded warrants is negligible and the pre-funded warrants are fully vested and exercisable.
The following table is a reconciliation of the share amounts used in calculating basic and diluted earnings (loss) per share:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Weighted-average common shares outstanding - Basic
130,522,399 126,997,384 129,947,615 126,519,777 
Effect of dilutive securities
5,375,847 — 6,003,245 — 
Weighted-average common shares outstanding - Diluted
135,898,246 126,997,384 135,950,860 126,519,777 
The Company's potential dilutive securities include unvested RSUs and unvested performance-based RSUs for which established performance criteria have been achieved as of the end of the respective periods, vested and unvested options to purchase common stock, and shares to be issued under the Company's employee stock purchase plan (ESPP). Certain of these potential dilutive securities have been excluded from the calculation of diluted net income (loss) per common share as the effect would be anti-dilutive.
The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net income (loss) per share for the periods presented due to their antidilutive effect:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Stock options to purchase common stock1,911,509 6,922,441 1,882,027 6,922,441 
RSUs subject to future vesting1,982,226 6,582,460 1,696,226 6,582,460 
ESPP shares subject to future issuance86,126 22,479 82,243 22,479 
Total3,979,861 13,527,380 3,660,496 13,527,380